CD274 and neoplasm: This strategy demonstrated greater resistance to PD-1/PD-L1 pathway inhibition, characterized by reduced inhibitory receptor expression and a less differentiated phenotype, resulting in more potent anti-tumor activity compared to single-target CAR-T cells 93.